Hyderabad: US-based biopharma giant Amgen flagged off its first India investment with a new technology and innovation centre in Hyderabad.

Global biotech leader Amgen opened its $200 million technology and innovation centre in Hyderabad, a facility that will help the U.S. firm ramp up digital capabilities, open more opportunities for the talent pool of the region and build on the city’s position as an emerging hub for global capability centres (GCC).

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.

HYDERABAD: US-based biopharma giant on Monday opened its new technology and innovation centre in Hyderabad with its CEO Robert Bradway announcing a $200 million (approx Rs 1600 crore) investment commitment in the facility through 2025 with additional investments planned in future years.

Amgen India opens in Hyderabad, investing $200 million in technology and innovation to advance global healthcare.

The facility, which occupies approximately 524,000 square feet across two towers in HITEC City, will focus on harnessing AI, data science, and digital innovation to accelerate research and development

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site.

Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the sites inauguration,

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert Bradway said at the inauguration of the site on Monday.